Download PDF
Horm Metab Res 2002; 34(1): 36-39
DOI: 10.1055/s-2002-19965
Original Clinical

© Georg Thieme Verlag Stuttgart · New York

Induction of TSH-Receptor Antibodies in Patients with Toxic Multinodular Goitre by Radioiodine Treatment

H.  Wallaschofski 2 , D.  Müller 1 , P.  Georgi 1 , R.  Paschke 2
  • 1Department of Nuclear Medicine, University of Leipzig, Germany
  • 2Department of Internal Medicine III, University of Leipzig, Germany
Further Information

Publication History

5 June 2001

5 September 2001

Publication Date:
14 August 2002 (online)

Also available at
    Permissions and Reprints

Abstract

Previous studies have indicated pre-existing subclinical Graves' disease (GD) in many patients with the scintigraphic diagnosis of disseminated thyroid autonomy (DISA) or toxic multinodular goitre (TMG) type A. After radioiodine (RAI) treatment, an increase or the induction of TSH-receptor antibodies (TRAbs) in patients with GD or TMG has been repeatedly reported.

In the present study, we investigated whether RAI could induce TRAbs in patients with TMG in whom pre-existing GD was excluded with highly sensitive TBII and TSAB assays. Therefore, TRAbs, anti-thyroperoxidase antibodies (anti-TPO-Abs) and anti-thyroglobulin antibodies (anti-TG-Abs) were determined in 43 consecutive patients at the nuclear medicine outpatient clinic with the scintigraphic diagnosis of toxic adenoma (TA; n = 20) or TMG type A (n = 11) or type B (n = 12) before and after RAI treatment. After RAI therapy, we detected TRAbs in 36 % (4 of 11) of patients with TMG type A only, whereas TRAbs were not detectable in patients with TMG type B or in patients with TA. Furthermore, 3 of the 4 patients with detectable TRAbs after RAI showed positive anti-TPO-Abs before RAI therapy. These findings provide further evidence for pre-existing GD in patients with TMG type A or DISA as previously suggested. Therefore, patients with TMG type A and high anti-TPO-Abs seem to be at increased risk of developing TRAbs or side-effects such as relapse of hyperthyroidism or thyroid associated ophthalmopathy. These patients therefore require more frequent evaluation after RAI treatment.

Key words

Radioiodine Treatment - TSH-Receptor Antibodies - Toxic Adenoma - Toxic Multinodular Goitre - Graves' Disease

References

  • 1 DeGroot L J. Radioiodine and the immune system.  Thyroid. 1997;  7 259-264
    PubMedGoogle Scholar
  • 2 Nygaard B, Faber J, Veje A, Hegedus L, Hansen J M. Appearance of Graves'-like disease after radioiodine therapy for toxic as well as non-toxic multinodular goitre.  Clin Endocrinol (Oxf). 1995;  43 129-130
    PubMedGoogle Scholar
  • 3 Nygaard B, Knudsen J H, Hegedus L, Scient A V, Hansen J E. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter.  J Clin Endocrinol Metab. 1997;  82 2926-2930
    CrossrefPubMedGoogle Scholar
  • 4 Nygaard B, Faber J, Veje A, Hegedus L, Hansen J M. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.  Thyroid. 1999;  9 477-481
    CrossrefPubMedGoogle Scholar
  • 5 Nygaard B, Metcalfe R A, Phipps J, Weetman A P, Hegedus L. Graves' disease and thyroid associated ophthalmopathy triggered by 131I treatment of non-toxic goiter.  J Endocrinol Invest. 1999;  22 481-485
    PubMedGoogle Scholar
  • 6 Boddenberg B, Voth E, Schicha H. (Immunogenic hyperthyroidism following radioiodine ablation of a focal autonomy).  Nuklearmedizin. 1993;  32 18-22
    PubMedGoogle Scholar
  • 7 Chiovato L, Santini F, Vitti P, Bendinelli G, Pinchera A. Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre (see comments).  Clin Endocrinol (Oxf). 1994;  40 803-806
    PubMedGoogle Scholar
  • 8 Smyth P P, Neylan D, McMullan N M, Smith D F, McKenna T J. Sequential presentation of a case of hyperthyroidism with autonomously functioning nodules and Graves' disease in the presence of IgG thyroid stimulators.  Acta Endocrinol (Copenh). 1988;  118 474-478
    PubMedGoogle Scholar
  • 9 Wallaschofski H, Orda C, Georgi P, Paschke R. Distinction between autoimmune and nonautoimmune hyperthyroidism by determination of TSH-receptor antibodies in patients with the initial diagnosis of toxic multinodular goitre.  Horm Metab Res. 2001;  33 504-507
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Kraiem Z, Glaser B, Yigla M, Pauker J, Sadeh O, Sheinfeld M. Toxic multinodular goiter: a variant of autoimmune hyperthyroidism.  J Clin Endocrinol Metab. 1987;  65 659-664
    CrossrefPubMedGoogle Scholar
  • 11 Meller J, Jauho A, Hufner M, Gratz S, Becker W. Disseminated thyroid autonomy or Graves' disease: reevaluation by a second generation TSH receptor antibody assay.  Thyroid Dec. 2000;  10 1073-1079
    CrossrefPubMedGoogle Scholar
  • 12 Wallaschofski H, Kaczmarek M, Miehle K, Hentschel B, Paschke R. Differences between thyrotropin receptor antibody bioactivity and inhibition of 125I-bovine thyrotropin binding.  Thyroid. 2000;  10 897-907
    PubMedGoogle Scholar
  • 13 Weetman A P. Graves' disease by any other name?.  Thyroid. 2000;  10 1071-1072
    PubMedGoogle Scholar
  • 14 Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs.  Thyroid. 1998;  8 119-124
    PubMedGoogle Scholar
  • 15 Schleusener H, Schwander J, Fischer C, Holle R, Holl G, Badenhoop K, Hensen J, Finke R, Bogner U, Mayr W R. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease [published erratum appears in Acta Endocrinol (Copenh) 1989 Aug; 121 (2): 304].  Acta Endocrinol (Copenh). 1989;  120 689-701
    PubMedGoogle Scholar
  • 16 Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.  Thyroid. 1997;  7 369-375
    CrossrefPubMedGoogle Scholar
  • 17 Weetman A P. Medical Progress: Graves' Disease.  N Engl J Med. 2000;  343 1236-1248
    CrossrefPubMedGoogle Scholar
  • 18 Wallaschofski H, Paschke R. Detection of thyroid stimulating (TSAB)- and thyrotropin stimulation blocking (TSBAB)-antibodies with CHO cell lines expressing different TSH-receptor numbers.  Clin Endocrinol (Oxf). 1999;  50 365-372
    CrossrefPubMedGoogle Scholar
  • 19 Chazenbalk G D, Pichurin P, McLachlan S M, Rapoport B. A direct binding assay for thyrotropin receptor autoantibodies.  Thyroid. 1999;  9 1057-1061
    CrossrefPubMedGoogle Scholar
  • 20 Sanders J, Oda Y, Roberts S, Kiddie A, Richards T, Bolton J, McGrath V, Walters S, Jaskolski D, Furmaniak J, Smith B R. The interaction of TSH receptor autoantibodies with 125I-labelled TSH receptor.  J Clin Endocrinol Metab. 1999;  84 3797-3802
    CrossrefPubMedGoogle Scholar
  • 21 Yamano Y, Takamatsu J, Sakane S, Hirai K, Kuma K, Ohsawa N. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.  Thyroid. 1999;  9 769-773
    PubMedGoogle Scholar
  • 22 Ludgate M. Animal models of Graves' disease.  European Journal of Endocrinology. 2000;  142 1-8
    CrossrefPubMedGoogle Scholar

Prof. Dr. med. R. Paschke

Universität Leipzig · Zentrum für Innere Medizin · Medizinische Klinik und Poliklinik III

Phillip-Rosenthal-Str. 27 · 04103 Leipzig · Germany

Phone: + 49 (341) 97-13200

Fax: + 49 (341) 97-13209

Email: pasr@medizin.uni-leipzig.de

      >